Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangluoning plaster is a Traditional Chinese Medicine (TCM) topical formulation developed by Longhua Hospital affiliated with the Shanghai University of Traditional Chinese Medicine. It is specifically indicated for the treatment of diabetic peripheral neuropathy (DPN), a condition characterized in TCM as Xiaoke Bi syndrome. The plaster is designed to be applied to specific acupuncture points or affected areas to tonify Qi, nourish Yin, and activate blood circulation to unblock collaterals. Pharmacologically, it is thought to work by improving local microcirculation, increasing nerve conduction velocity, and reducing the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), while potentially upregulating neurotrophic factors like Nerve Growth Factor (NGF). It serves as a non-invasive adjuvant therapy to standard glycemic control for managing neuropathic symptoms like pain, numbness, and coldness in the extremities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tangluoning plaster.